NASDAQ · STOCK
Edwards Lifesciences
$91.46
52W $72.30 – $96.29
61/100
$53.92B
49.1
0.83
Price History (6M)
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Executive Summary
6 analysts weighed in with 67% agreement on a bullish lean. Risk Analyst: Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock. Value Analyst: P/E of 49.1 is expensive by classic value standards. Overall recommendation: BUY.
Executive Summary
6 analysts weighed in with 67% agreement on a bullish lean. Risk Analyst: Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock. Value Analyst: P/E of 49.1 is expensive by classic value standards. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily trend: uptrend.
- Weekly trend: uptrend.
- Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Stochastic RSI (82.5) confirms overbought conditions.
- Risk/reward is unfavorable: 8.6% downside vs 1.3% upside.
AI Investment Committee
Committee Consensus
As of July 07, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 49.1 is expensive by classic value standards
Growth Analyst
neutral
57
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -73.2% YoY despite any revenue growth
Technical Analyst
bullish
63
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
63
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.17 across 12 articles, 14d)
Technical Analysis
RSI (14)
65.9
Neutral
MACD Histogram
0.488
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$85.58
Resistance
$94.87
Bollinger %B
0.82
Inside Bands
Price vs Moving Averages
EMA 9
$92.53
Below
EMA 21
$90.10
Above
EMA 50
$87.11
Above
EMA 200
$82.90
Above
Fundamental Analysis
Valuation
25
Growth
57
Profitability
80
Financial Health
100
Valuation
P/E Ratio
49.1×
P/B Ratio
4.79×
PEG Ratio
—
Dividend Yield
—
52W High
$96.29
52W Low
$72.30
Quality & Growth
ROE
1059.0%
ROA
815.0%
Gross Margin
7787.0%
Operating Margin
1708.0%
Revenue Growth YoY
+1381.0%
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 49.1 (rich relative to a 15-40x range); Price-to-book of 4.8x; Revenue growth (YoY) of 13.8%; EPS growth (YoY) of -73.2%; Return on equity of 10.6%; Return on assets of 8.2%; Net margin of 17.4%; Gross margin of 77.9%; Current ratio of 3.72 (healthy short-term liquidity); Debt-to-equity of 0.06; Most recent quarter beat estimates by 4.2%; EPS growth accelerating (-13.4% -> +34.5% QoQ); Analyst estimates rising over recent quarters
Key Risks
- Stochastic RSI (82.5) confirms overbought conditions.
- Risk/reward is unfavorable: 8.6% downside vs 1.3% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full EW Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile